Pharmaceutical Technology

APRIL 11, 2023

The approval enables the company to manufacture and market azithromycin to treat infections such as bronchitis, pneumonia and sexually transmitted diseases (STDs). The vaccine, which generates the SARS-CoV-2 viral spike protein on administration, induces the immune system’s cellular and humoral arm-mediated immune response.

FDA Approval 130

FDA Approval Drugs Immune Response Manufacturing 130

Pharmaceutical Technology

JANUARY 19, 2023

Nuvaxovid is a protein-based vaccine created from the genetic sequence of the initial SARS-CoV-2 virus strain. The expanded manufacturing and marketing approval was based on the data obtained from the Phase II trial, conducted in Australia and the US; a separate Phase II trial held in South Africa; and the UK-sponsored COV-BOOST trial.

Vaccine 147

Vaccine Vaccination Immune Response Protein 147

World of DTC Marketing

APRIL 11, 2021

Based on the virus a number of vaccines targeting the spike protein were designed, tested in animal models and found to be quite promising against SARS and other coronavirus illnesses like Middle East respiratory syndrome. However, the continued study of the virus was shelved because of the lack of funding.

Vaccine 303

Vaccine Vaccination Clinical Trials Clinical Trials 303

pharmaphorum

DECEMBER 4, 2020

Under the agreement Valneva could receive up to $308 million in cash payments, after Pfizer paid $130 million up front for marketing rights to the vaccine if it succeeds in the clinic. OspA is one of the most dominant surface proteins expressed by the bacteria when present in the ticks that spread the disease.

Vaccine 119

Vaccine Vaccination Bacterium Protein 119

Pfizer

JULY 26, 2022

Pfizer and BioNTech Advance COVID-19 Vaccine Strategy With Study Start of Next-Generation Vaccine Candidate Based on Enhanced Spike Protein Design. Pfizer and BioNTech Advance COVID-19 Vaccine Strategy With Study Start of Next-Generation Vaccine Candidate Based on Enhanced Spike Protein Design. deliesschef. Tue, 07/26/2022 - 17:41.

Vaccine 111

Vaccine Vaccination Protein Immune Response 111

pharmaphorum

SEPTEMBER 30, 2020

This first data comes from a descriptive analysis from the seamless phase 1/2/3 trial that Regeneron hopes will hurry the medicine dubbed REGN-COV2 to market. As expected, patients in the study formed two populations: those who had already mounted an immune response and those whose immune response was not yet adequate.

Antibody 135

Antibody Immune Response Trials Protein 135

pharmaphorum

FEBRUARY 22, 2021

In December interim phase 1/2 trial results showed the vaccine produced a lower immune response in older adults. At the time analysts said that this was likely due to an insufficient concentration of the antigen and the companies have refined their antigen formulation hoping for a better immune response including in older adults.

Vaccine 89

Vaccine Vaccination Recombinant DNA Technology Trials 89

The Pharma Data

JUNE 29, 2021

A sub-analysis from the Oxford-led COV001 and COV002 trials with Vaxzevria induced strong immune responses following either a prolonged second dose interval of up to 45 weeks or following a third boosting dose. There is an excellent response to a second dose, even after a 10 month delay from the first.”.

Immune Response 52

Immune Response Vaccine Vaccination Antibody 52

pharmaphorum

NOVEMBER 23, 2021

The two had been working on a COVID-19 vaccine, which showed promise in early-stage clinical testing, but shelved the project in September after deciding it would be too late to a market already dominated by rival shots from Pfizer/BioNTech and Moderna. Specific financial terms have not been disclosed.

Licensing 105

Licensing Licensing Vaccine Vaccination 105

XTalks

OCTOBER 11, 2024

The vaccine uses recombinant RSV glycoprotein F, stabilized in its prefusion conformation (RSVPreF3), along with GSK’s AS01E adjuvant to boost the immune response — the same adjuvant used in Shingrix, its shingles vaccine, but at a lower dose. Nevertheless, GSK maintains its market lead.

Vaccine 103

Vaccine Vaccination Immune Response Trials 103

XTalks

DECEMBER 12, 2024

Its the first FDA-cleared host-immune response assay for accurately distinguishing between bacterial and viral infections in just 15 minutes. MeMeds new Severity sepsis test also leverages advanced immunoassay technology to analyze specific host-response proteins to provide rapid, reliable results.

In-Vitro 92

In-Vitro Immune Response Protein Sales 92

pharmaphorum

JULY 20, 2021

The vaccine – now dubbed Vidprevtyn – is based on a recombinant protein antigen developed by Sanofi’s vaccines unit Sanofi Pasteur, and also includes an immune-boosting adjuvant developed by GSK that aims to boost its efficacy. 1.351) variant first identified in South Africa.

Vaccine 98

Vaccine Vaccination Protein Immune Response 98

Pharmaceutical Technology

JULY 29, 2022

Once new vaccines for the Omicron variant are approved, they will partly make up for the waning interest in older Covid boosters in developed markets. Bivalent vaccines work by stimulating an immune response against two different antigens, whereas monovalent vaccines only target one antigen. Commercial dose manufacturing.

Manufacturing 130

Manufacturing Vaccine Vaccination Packaging 130

XTalks

JUNE 5, 2023

Abrysvo is an unadjuvanted vaccine and is composed of two preF proteins selected to optimize protection against RSV A and B strains. “A In February 2023, Pfizer revealed that the European Medicines Agency (EMA) has accepted the Marketing Authorization Application (MAA) for Abrysvo. billion in value by 2024, and grow to $9.53

Vaccine 98

Vaccine Vaccination FDA Approval Protein 98

The Pharma Data

APRIL 15, 2022

BioNTech is the Marketing Authorization Holder in the United States, the European Union, the United Kingdom, Canada and the holder of emergency use authorizations or equivalents in the United States (jointly with Pfizer) and other countries.

Immune Response 52

Immune Response Vaccine Vaccination Clinical Trials 52

pharmaphorum

AUGUST 23, 2021

DNA vaccines work by delivering a genetically-engineered plasmid containing the DNA sequence encoding the desired antigen – in this case the SARS-CoV-2 spike protein – which is then taken up by cells. Proponents of the approach claim that DNA vaccines may have advantages over other technologies like mRNA.

DNA 98

DNA Vaccine Vaccination Genetic Engineering 98

Cloudbyz

MARCH 5, 2024

Biologics: Biologics are large, complex molecules, often proteins, that are produced using living cells. Mode of Action : Small Molecules: They often work by binding to specific sites on target proteins to inhibit or activate their function, which can affect various biological pathways inside the cell.

Development 97

Development Drugs Immune Response Manufacturing 97

pharmaphorum

AUGUST 16, 2020

Last month, interim results from a phase 1/2 trial of ChAdOx1 were published in The Lancet and showed the jab was tolerated and generated immune responses against the SARS-CoV-2 virus in all vaccinated participants.

Vaccine 111

Vaccine Vaccination Immune Response Trials 111

XTalks

APRIL 7, 2021

The new, revised EUA will allow the company to market the test for the qualitative detection of SARS-CoV-2 from nasal swab samples for screening use with serial testing. The test is intended for the detection of COVID-19 infection, either a recent or previous infection, as detected through an adaptive antibody immune response to SARS-CoV-2.

Antibody 102

Antibody Immune Response Radiology Marketing 102

pharmaphorum

JULY 14, 2021

The shot also includes two “conserved” pneumococcal proteins – antigens that seem always to be present in the bacterium regardless of its serotype, so could potentially provide protection against an even broader range.

Immune Response 52

Immune Response Vaccine Vaccination Protein 52

Pharmaceutical Technology

AUGUST 24, 2022

More than three decades ago, scientists at the National Cancer Institute began exploring ways to fight cancer using the patient’s immune system. The global immunotherapy market, which includes CAR T-cell therapy, adoptive cell therapies, checkpoint inhibitors, monoclonal antibodies, and other immunotherapies, is expected to grow by 10.1%

Clinical Trials 130

Clinical Trials Clinical Trials Trials Development 130

pharmaphorum

JUNE 14, 2021

AstraZeneca meanwhile has already said that it may forego the EUA approach for its AZD1222 vaccine and go straight for a full marketing application. It is also testing another version of the vaccine that has shown stronger immune responses against beta and other variants and could also be used as a booster shot.

Vaccine 84

Vaccine Vaccination Immune Response Protein 84

Cloudbyz

MARCH 6, 2024

Understanding Biologics: Biologics are a class of therapeutic agents derived from living organisms, such as cells, tissues, or proteins. Personalized Medicine: Biologics offer the potential for personalized treatment approaches by taking into account individual variations in genetics, immune responses, and disease characteristics.

Gene 99

Gene Immune Response Manufacturing Gene Therapy 99

pharmaphorum

JULY 9, 2021

The results are encouraging as beta has been shown to be the most likely of the variants identified to date to evade the immune response generated by COVID-19 vaccines, while delta is more transmissible and – according to federal data – accounted for almost 52% of all COVID-19 infections in the two weeks to 3 July. .

Vaccine 98

Vaccine Vaccination Antibody Immune Response 98

pharmaphorum

NOVEMBER 2, 2020

In January, Google DeepMind debuted AlphaFold, a deep-learning system that predicts the structure of several under-studied proteins, including those associated with COVID-19. It has helped determine the availability of current drugs on the market that could be repurposed to treat COVID-19.

Nurses 132

Nurses Scientist Clinical Trials Clinical Trials 132

XTalks

OCTOBER 25, 2022

Imjudo is an anti-cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) monoclonal antibody that blocks the action of CTLA-4. Inhibition of the protein aids in T-cell activation to prime the immune system against cancer cells to induce their death.

FDA Approval 98

FDA Approval Trials Drugs Immune Response 98

pharmaphorum

MAY 27, 2021

GSK and Sanofi think they could be on track for approval of the recombinant protein-based vaccine – delivered with GSK’s immune-response boosting adjuvant – before the end of the year. The phase 3 trial will include one shot targeting the original SARS-CoV-2 virus as well as a second against the B.1.351

Antibody 59

Antibody Immune Response Vaccine Vaccination 59

Pharmaceutical Technology

MARCH 24, 2023

Fox says adjuvant protein subunit vaccines can be a safer approach compared to live attenuated virus vaccines as there is a minimized risk of developing side effects. Using an adjuvant with an antigen can give specific tailored and potent immune responses, he adds. Please check your email to download the Report.

Vaccine 162

Vaccine Vaccination Clinical Trials Clinical Trials 162

Delveinsight

SEPTEMBER 8, 2021

As per DelveInsight’s report on Benlysta (Belimumab) market forecast , the sale of Belimumab has kept on increasing year after year. Currently, the SLE therapeutics market is revolving around only one drug i.e It is the top-selling medication in the market. Anifrolumab (MEDI-546). Baricitinib (INCB-028050).

Marketing 52

Marketing Sales FDA Approval Antibody 52

The Pharma Data

JANUARY 21, 2021

Luckily, the new variants still rely on the coronavirus’ “spike protein” to infect cells, and the two COVID vaccines now on the U.S. market specifically target the spike protein to prevent transmission, explained Dr. Kathryn Edwards, scientific director of the Vanderbilt University Vaccine Research Program in Nashville.

Vaccine 52

Vaccine Vaccination Protein Immune Response 52

XTalks

MAY 1, 2023

Qalsody contains tofersen, an antisense oligonucleotide that specifically targets the mRNA made from mutated SODI genes to prevent the formation of toxic SOD1 proteins. Reduction in these two biomarkers in response to tofersen is believed to predict clinical benefit for patients. How Does Qalsody Work?

FDA Approval 89

FDA Approval Gene Genetics Protein 89

pharmaphorum

MAY 31, 2022

billion takeover of US biotech Affinivax, buying a pneumococcal vaccine candidate that is aiming to break into a market that for years has been dominated by Pfizer’s Prevnar franchise. The biotech says this can stimulate both B cell (antibody) and T cell immune responses with a single shot. GlaxoSmithKline has agreed a $3.3

Vaccine 52

Vaccine Vaccination Bacterium Sales 52

Roots Analysis

AUGUST 23, 2024

Unveiling The Potential of mRNA Technology mRNA is a single-stranded molecule that relays the genetic instructions needed to make proteins from DNA in the cell nucleus to ribosomes. Ribosomes are cellular machines that read mRNA sequences and produce proteins. There are several advantages to approaching vaccination this way.

Protein 40

Protein Vaccine Vaccination Immune Response 40

pharmaphorum

SEPTEMBER 15, 2020

The UK also has deals covering 30 million doses of Pfizer/BioNTech’s mRNA-based candidate , 60 million doses of adjuvanted protein subunit vaccine candidate being developed by GlaxoSmithKline and Sanofi Pasteur, 30 million of a Johnson & Johnson jab and 60 million of another candidate from Novavax.

Vaccine 80

Vaccine Vaccination Immune Response Manufacturing 80

Advarra

JANUARY 11, 2024

Adoptive T Cell therapies, therapeutic antibodies, and immunomodulatory proteins represent just some of the potentially beneficial treatment strategies for successful mRNA cancer trials. The mRNA constructs used in COVID-19 vaccines, for example, direct cells to produce a version of the “spike” protein studding the surface of SARS-CoV-2.

Vaccine 52

Vaccine Vaccination Protein Antibody 52

pharmaphorum

FEBRUARY 25, 2021

The first trial showed that it could increase levels of Treg cells thought to be involved in dampening down immune responses.

Clinical Trials 71

Clinical Trials Clinical Trials Immune Response Trials 71

pharmaphorum

MARCH 17, 2022

.” Both Pfizer’s BioNTech-partnered Comirnaty and Moderna’s SpikeVax vaccines use LNPs to carry mRNA coding for the SARS-CoV-2 spike protein. After dosing, the LNPs deliver the mRNA sequence into cells, which is then used by cellular machinery to manufacture the viral protein and stimulate an immune response.

Vaccine 52

Vaccine Vaccination Sales Immune Response 52